Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3629271 | 1.00 | MAPK1 (0.32) | MAPK1CCR5 | |
| SCHEMBL1449497 | 0.97 | CCR5 (0.33) | CCR5 | |
| SCHEMBL23505391 | 0.90 | — | — | |
| SCHEMBL702038 | 0.90 | — | — | |
| SCHEMBL17652515 | 0.83 | — | — | |
| SCHEMBL1947185 | 0.83 | — | — | |
| SCHEMBL23253901 | 0.83 | — | — | |
| SCHEMBL56633 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL29500392 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL5241311 | 0.80 | CCR5 (0.35) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584110-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2018-07-26 | — | — | US | disclosed |
| US-9878991-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-30 | — | — | US | disclosed |
| EP-2709609-B1 | HETEROCYCLIC COMPOUNDS | SHIONOGI & CO (JP) | 2017-10-04 | — | — | EP | disclosed |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2016-12-08 | — | — | US | disclosed |
| US-9365563-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2604598-B1 | TRPV1 antagonists and uses thereof | PURDUE PHARMA LP (US) | 2016-04-06 | — | — | EP | disclosed |
| US-9156830-B2 | Heterocyclic compounds | SHIONOGI & CO., LTD. (JP) | 2015-10-13 | — | — | US | disclosed |
| US-8921373-B2 | Compounds having TRPV1 antagonistic activity and uses thereof | SHIONOGI & CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8889690-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130338170-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8575199-B2 | Formula (IA″) compounds comprising (piperidin-4-yl)pyridine or (1,2,3,6-tetrahydropyridin-4-4yl) as TRPV1 antagonists | PURDUE PHARMA L.P. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8476277-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2604599-A1 | TRPV1 antagonists and uses thereof | Purdue Pharma LP (US) | 2013-06-19 | — | — | EP | disclosed |
| EP-2604598-A1 | TRPV1 antagonists and uses thereof | Purdue Pharma L.P. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | PURDUE PHARMA L.P. | 2013-05-16 | — | — | US | disclosed |
| US-20120177570-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L. P. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338170-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | MAPK1 1863/4885CCR5 398/4885 |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | MAPK1 1863/4885CCR5 398/4885 |
| US-20120177570-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV2 | MAPK1 2488/4885CCR5 465/4885 |
| US-20090176796-A1 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV2 | MAPK1 2488/4885CCR5 465/4885 |
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | TRPV1, TRPA1, TRPV2 | MAPK1 1718/4885CCR5 340/4885 |
| US-20090170868-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | MAPK1 1863/4885CCR5 398/4885 |
| US-20160355499-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | MAPK1 1863/4885CCR5 398/4885 |
| US-10584110-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | TRPV1, TRPA1, TRPV5 | MAPK1 1863/4885CCR5 398/4885 |
| US-20090170867-A1 | TRPV1 ANTAGONISTS INCLUDING SULFONAMIDE SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | MAPK1 2187/4885CCR5 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.